Fluicell AB (OSTO:FLUI) 5-Year Yield-on-Cost %: 0.00 (As of Jul. 18, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:FLUI Fluicell AB OSTO:FLUI
51 GF Score
Price kr33.00
GF Value kr34.23
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Fluicell AB 5-Year Yield-on-Cost %?

Fluicell AB OSTO:FLUI -5.44% 51 5-Year Yield-on-Cost % is 0.00 as of Jul. 18, 2026. GuruFocus rates OSTO:FLUI with a GF Score™ of 51/100 and a GF Value™ of kr34.23 (Fairly Valued). The stock has 4 warning signs investors should review. Among 152 Biotechnology companies, Fluicell AB ranks worse than 657894.08% on this metric.

Fluicell AB's yield on cost for the quarter that ended in Mar. 2026 was 0.00.


The historical rank and industry rank for Fluicell AB's 5-Year Yield-on-Cost % or its related term are showing as below:



OSTO:FLUI's 5-Year Yield-on-Cost % is not ranked *
in the Biotechnology industry.
Industry Median: 1.73
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Fluicell AB  (OSTO:FLUI) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Fluicell AB 5-Year Yield-on-Cost % Related Terms


OSTO:FLUI vs VRTX, REGN, ALNY: 5-Year Yield-on-Cost % Comparison

For the Biotechnology subindustry, Fluicell AB's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fluicell AB 5-Year Yield-on-Cost % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fluicell AB's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Fluicell AB's 5-Year Yield-on-Cost % falls into.


OSTO:FLUI
51GF Score
Fluicell AB OSTO:FLUI
5-Year Yield-on-Cost % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fluicell AB 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Fluicell AB is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5
Frequently Asked Questions Learn more about 5-Year Yield-on-Cost % →
What does a 5-Year Yield-on-Cost % of 0.00 mean?
Fluicell AB (OSTO:FLUI) has a 5-Year Yield-on-Cost % of 0.00 as of Jul. 18, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Fluicell AB and its competitors. According to the industry distribution chart, Fluicell AB ranks #999999 out of 152 companies in the Biotechnology industry.
Is Fluicell AB's 5-Year Yield-on-Cost % too high?
Fluicell AB's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Fluicell AB ranks #999999 out of 152 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Fluicell AB has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fluicell AB's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fluicell AB ranks #999999 out of 152 companies for 5-Year Yield-on-Cost %. This places Fluicell AB in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.73. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.73, based on 152 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Fluicell AB and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fluicell AB's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fluicell AB stock overvalued right now?
Based on GuruFocus' analysis, Fluicell AB (OSTO:FLUI) is currently considered Fairly Valued. The stock's GF Value™ is kr34.23, compared to a current price of kr33.00 — trading 3.6% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Fluicell AB's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Fluicell AB (OSTO:FLUI), the current 5-Year Yield-on-Cost % is 0.00 as of Jul. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fluicell AB (OSTO:FLUI) Overvalued in 2026?

Based on GuruFocus' analysis, Fluicell AB stock appears to be undervalued. The current stock price of kr33.00 is trading 3.6% below its estimated GF Value™ of kr34.23. GuruFocus considers Fluicell AB to be Fairly Valued.

Key valuation signals for OSTO:FLUI:

  • 5-Year Yield-on-Cost %: 0.00
  • GF Value™: kr34.23 vs. price of kr33.00 (3.6% below fair value)
  • GF Score™: 51/100 with 4 warning signs

No single metric tells the full story. See the OSTO:FLUI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fluicell AB Business Description

Other Exchanges 5J90:Germany
Address Flojelbergsgatan 8C, Molndal, Gothenburg, SWE, 431 37
Fluicell AB is a Swedish life science company that conducts development in regenerative medicine and human tissue-based screening models for drug development, with a particular focus on the areas of type 1 diabetes, cardiac safety screening models, and kidney diseases. The company's platform for the production of human tissue that is based on Fluicell's technology for high-resolution 3D bioprinting, and which enables the creation of tissue-based products for use in drug development and regenerative medicine.
51GF Score

Get the complete analysis for OSTO:FLUI

5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr33.00
Price
kr34.23
GF Value